Chlamydia prevalence among women and men entering the National Job Training Program: United States, 2003-2007.
OBJECTIVE
To analyze 5-year prevalence trends in Chlamydia trachomatis infections among high-risk young men and women aged 16 to 24 years entering the National Job Training Program, where universal screening is required.


METHODS
Entrance exams conducted in over 100 National Job Training Program centers from 2003 to 2007 were considered. Women provided cervical specimens tested using either a DNA hybridization probe (PACE 2, Gen-Probe, San Diego, CA) or a strand displacement amplification test (SDA, BD ProbeTec ET, Becton-Dickinson, Sparks, MD). In the absence of a pelvic exam, urine specimens were tested using SDA. PACE 2 testing was performed predominately from 2002 to 2005; from 2005 to 2007, SDA was used. All male testing was conducted using SDA on urine specimens. Chlamydia prevalence trends were assessed for women and men, using logistic regression models. Adjusted odds ratios (AOR), 95% confidence intervals (CI), and P-values were calculated.


RESULTS
Approximately 15,000 women and 30,000 men were screened annually for chlamydia. Among both sexes, adjusted prevalence declined significantly from 2003 to 2007. In 2003, crude prevalence among women was 9.9%; in 2007, prevalence was 13.7%. However, after controlling for covariates, including increasingly sensitive tests, the model indicated a significant declining prevalence trend (AOR: 0.95, CI: 0.93-0.97, 4.6% decrease in odds per year). Among men, crude prevalence in 2003 was 8.4%; in 2007, prevalence was 8.3%; after controlling for possible confounding, a significant decline in prevalence was also detected (AOR: 0.98, CI: 0.96-0.99, 1.9% decrease in odds per year).


CONCLUSIONS
In a relatively stable, high-risk population of young women and men, adjusted chlamydia prevalence declined from 2003 to 2007. Test technology plays a critical role in interpreting rates and should be considered whenever chlamydia rates are examined.
Division of STD Prevention, CDC, Atlanta, GA 30333, USA. clindsey@cdc.gov
Catherine Lindsey
CL
Satterwhite
Lin H
LH
Tian
Jimmy
J
Braxton
Hillard
H
Weinstock
D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000382:microbiology; D002690:Chlamydia Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D004493:Education; D004651:Employment; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening; D021141:Nucleic Acid Amplification Techniques; D015995:Prevalence; D014481:United States / Q000453:epidemiology; D014556:Urine / Q000382:microbiology; D014626:Vaginal Smears; D055815:Young Adult